Its ironic then that they bought on 4/30 and by 6/30, their 6/30 filing shows they have sold out of all 600,000 shares they owned. I guess they dumped and ran.
Why did your broker suggest this stock? I'm surprised that a broker would suggest a biotech with only one product and not even selling that product yet. Why didn't he suggest something like celg?
Its all good, just needed something to joke about now that the information flow has dried up.
I'm thinking of selling half my shares now and letting the other 85 shares ride till next year.
Maybe adam feuerstein will write an article about this and give me an entry point a dollar lower.
This is incorrect. They monetized their Kadcyla for 200 million, and said they are ending the year with 265 million. No need to do a cash raise, since burn is generally 100 million per year.
" We now expect to end the year with between $265 million and $275 million in cash and securities, compared to previous guidance of $75 million to $85 million."
probably an institution trade that was brokered during the day at 16.03 (either early in the day, or negotiated at the average for the day or something) and then just recorded in the after hours. After hours couldn't support that much buying/selling without seeing bids and asks all over the place.
We all are. Unless you have a margin call due today, place a buy order, close the screen and then go do something else. Virtually anything you buy will be up in 3 weeks.
I see the ask is 5.80 for a 10-strike call. Hopefully you can get them for lower than that, otherwise you're better off with stock. Did you get a fill under 5 dollars?
Thank you blue,
I am unclear about the specifics of one script- how long after a script a patient would have to refill? It is 1 month based on your $9492 value for the year, is that correct? When we receive numbers like two weeks ago, where it was 249 TRx, how can we figure out what the rate of renewal is?
you have a fatal flaw in your last paragraph where you say "so if kerx can get to 423 new scripts per week, they could make $1 eps": You earlier made the assumption that there is 100% refill rate, and we know that isn't true- in fact it's way lower.
I think that a takeout might come from a partner who sees promise in more than one of their drugs using IMGN technology. I'm thinking like novartis, etc. Such a company would have advanced notice of the success of the drugs, and rather than pay IMGN royalties that might total 800 million, it would be better to just spend the 800 million and buy the company, plus the regular premium. I think that these data don't make a compelling case to buy IMGN right now. Why gamble before approval, if it gets early approval then its easier to buy the company when the stock price is 18 dollars than 14 dollars without approval.
you're viewing this through all of our negatively-skewed IMGN glasses. There is a chance that these data will change how this stock is viewed. We've all been conditioned to view IMGN negatively over the past 2 years, but if the sentiment on the stock has changed, a premium for the company will be added to the stock.
i'll buy my puts tomorrow if it pops up to 16+. This much of a move on this much volume is going to leave a lot of people behind- shorts especially.